Inflammation, Perioperative Morbidity
Conditions
Keywords
steroid administration, tight glucose control, light anesthesiReducing inflammatory response to surgical stress, a
Brief summary
Evidence thus suggests that steroid administration, tight glucose control, and avoidance of deep anesthesia may decrease perioperative morbidity by reducing the inflammatory response to surgery. Using a three-way factorial approach, the investigators thus propose to test the primary hypotheses that major perioperative morbidity is reduced by: 1) low-dose dexamethasone; 2) intensive perioperative glucose control; and 3) lighter anesthesia. Secondary hypotheses include that each intervention reduces circulating concentrations of the inflammatory marker CRP, and that there is a correlation between C-reactive protein (CRP) and post-operative complications. Anesthetic sensitivity predicts major and minor complications, and delirium Other secondary hypotheses are that each intervention, reduces minor surgical complications, reduces postoperative nausea and vomiting (PONV), reduces postoperative delirium, speeds hospital discharge, improves quality of life (SF-12v2 Health Survey, Christensen's VAS fatigue score), and reduces all-cause one-year mortality.
Detailed description
The perioperative period is characterized by an intense inflammatory response marked by elevated concentrations of inflammatory markers like C-Reactive Protein (CRP). This response has been linked to increased perioperative morbidity and mortality. Available evidence suggests that blunting the inflammatory response to surgical trauma might improve perioperative outcomes. The putative benefits from blunting the surgical stress response are likely to be greatest in high-risk patients such as those having major non-cardiac surgery. We will study three interventions potentially modulating perioperative inflammation, corticosteroids, tight glucose control and light anesthesia and their effects on major morbidity and mortality resulting from major non-cardiac surgery. Steroids are the most powerful routinely available anti-inflammatory drugs. They decrease perioperative concentrations of inflammatory markers and improve outcomes after cardiac and abdominal surgery. Poorly controlled blood glucose worsens the inflammatory response to surgery. Hyperglycemia impairs wound healing, increases infection risk, increases overall hospital mortality, increases the risk of perioperative renal failure, and augments transfusion requirements. Treatment of hyperglycemia has been shown to improve outcomes and decrease mortality in cardiac patients. Also in critically ill patients, it decreased inflammatory markers, overall hospital mortality by 34%, blood stream infections by 46%, and acute renal failure by 41%. Cumulative deep hypnotic time is associated with increased one-year all-cause mortality, possibly through aggravation of the inflammatory response to surgery. In contrast, avoidance of deep anesthesia appears to reduce postoperative CRP levels, the risk of nausea and vomiting, as well as postoperative hemodynamic, respiratory and infectious complications. Evidence thus suggests that steroid administration, tight glucose control, and avoidance of deep anesthesia may decrease perioperative morbidity by reducing the inflammatory response to surgery. Using a three-way factorial approach, we thus propose to test the primary hypotheses that major perioperative morbidity is reduced by: 1) low-dose dexamethasone; 2) intensive perioperative glucose control; and, 3) lighter anesthesia. Secondary hypotheses include that each intervention reduces circulating concentrations of the inflammatory marker CRP, and that there is a correlation between CRP and post-operative complications. Anesthetic sensitivity predicts major and minor complications, and delirium Other secondary hypotheses are that each intervention, reduces minor surgical complications, reduces postoperative nausea and vomiting (PONV), reduces postoperative delirium, speeds hospital discharge, improves quality of life (SF-12v2 Health Survey, Christensen's VAS fatigue score), and reduces all-cause one-year mortality.
Interventions
8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning
Insulin to maintain blood glucose 80-110 mg/dl.
Light anesthesia to maintain BIS about 55
8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning
Insulin to maintain blood glucose 180-200 mg/dl.
Deep anesthesia to maintain BIS about 35
Sponsors
Study design
Eligibility
Inclusion criteria
1. Age ≥40 years old. 2. Major non-cardiac surgical procedures scheduled to take ≥ two hours done under general anesthesia. 3. Written informed consent
Exclusion criteria
1. Recent intravenous or oral steroid therapy (within 30 days); inhaled steroids are permitted 2. Any contraindications to the proposed interventions 3. ASA Physical Status \> 4 4. Non English speaking patients 5. Procedures done under regional anesthesia
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Major Perioperative Morbidity | 30 day after surgery | Our primary outcome was a collapsed composite endpoint (any versus none) defined as the occurrence of at least one of sixteen major complications before hospital discharge, including sepsis, severe surgical site infection, myocardial infarction, heart failure, stroke, unstable ventricular arrhythmias, pulmonary embolism, pneumonia, respiratory failure, dialysis dependent renal failure, large pleural or peritoneal effusions, major bleeding, major wound and surgical site healing complications, vascular graft thrombosis, and 30-day mortality. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| 1 Year Mortality | 1 year after surgery | All-cause mortality |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Intensive Glucose Control, Dexamethasone, Light Anesthesia * Intensive Glucose Control The target range for blood glucose will be 80-110 mg/dl
* Dexamethasone Dexamethasone administered at 8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning.
* Light anesthesia target BIS of 55
Dexamethasone Sodium Sulfate: 8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning
Insulin: Insulin to maintain blood glucose 80-110 mg/dl.
anesthesia management: Light anesthesia to maintain BIS about 55 | 52 |
| Intensive Glucose Control, Dexamethasone, Deep Anesthesia * Intensive Glucose Control The target range for blood glucose will be 80-110 mg/dl
* Dexamethasone Dexamethasone administered at 8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning.
* Deep anesthesia target BIS of 35
Dexamethasone Sodium Sulfate: 8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning
Insulin: Insulin to maintain blood glucose 80-110 mg/dl.
Anesthesia management -Placebo: Deep anesthesia to maintain BIS about 35 | 51 |
| Intensive Glucose Control, Placebo, Light Anesthesia * Intensive Glucose Control The target range for blood glucose will be 80-110 mg/dl
* Placebo Placebo administered at 8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning.
* Light anesthesia target BIS of 55
Dexamethasone Sodium Sulfate: 8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning
anesthesia management: Light anesthesia to maintain BIS about 55
Insulin - Placebo: Insulin to maintain blood glucose 180-200 mg/dl. | 47 |
| Conventional Glucose Control, Dexamethasone, Light Anesthesia * Conventional Glucose Control The target range for blood glucose will be 180-200 mg/dl
* Dexamethasone Dexamethasone administered at 8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning.
* Light anesthesia target BIS of 55
Insulin: Insulin to maintain blood glucose 80-110 mg/dl.
anesthesia management: Light anesthesia to maintain BIS about 55
Dexamethasone - placebo: 8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning | 46 |
| Intensive Glucose Control, Placebo, Deep Anesthesia * Intensive Glucose Control The target range for blood glucose will be 80-110 mg/dl
* Placebo Placebo administered at 8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning.
* Deep anesthesia target BIS of 35
Dexamethasone Sodium Sulfate: 8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning
Insulin - Placebo: Insulin to maintain blood glucose 180-200 mg/dl.
Anesthesia management -Placebo: Deep anesthesia to maintain BIS about 35 | 46 |
| Conventional Glucose Control, Dexamethasone, Deep Anesthesia * Conventional Glucose Control The target range for blood glucose will be 180-200 mg/dl
* Dexamethasone Dexamethasone administered at 8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning.
* Deep anesthesia target BIS of 35
Insulin: Insulin to maintain blood glucose 80-110 mg/dl.
Dexamethasone - placebo: 8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning
Anesthesia management -Placebo: Deep anesthesia to maintain BIS about 35 | 44 |
| Conventional Glucose Control, Placebo, Light Anesthesia * Conventional Glucose Control The target range for blood glucose will be 180-200 mg/dl
* Placebo Placebo administered at 8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning.
* Light anesthesia target BIS of 55
anesthesia management: Light anesthesia to maintain BIS about 55
Dexamethasone - placebo: 8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning
Insulin - Placebo: Insulin to maintain blood glucose 180-200 mg/dl. | 49 |
| Conventional Glucose Control, Placebo, Deep Anesthesia * Conventional Glucose Control The target range for blood glucose will be 180-200 mg/dl
* Placebo Placebo administered at 8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning.
* Deep anesthesia target BIS of 35
Dexamethasone - placebo: 8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning
Insulin - Placebo: Insulin to maintain blood glucose 180-200 mg/dl.
Anesthesia management -Placebo: Deep anesthesia to maintain BIS about 35 | 46 |
| Total | 381 |
Baseline characteristics
| Characteristic | Intensive Glucose Control, Dexamethasone, Light Anesthesia | Intensive Glucose Control, Dexamethasone, Deep Anesthesia | Intensive Glucose Control, Placebo, Light Anesthesia | Conventional Glucose Control, Dexamethasone, Light Anesthesia | Intensive Glucose Control, Placebo, Deep Anesthesia | Conventional Glucose Control, Dexamethasone, Deep Anesthesia | Conventional Glucose Control, Placebo, Light Anesthesia | Conventional Glucose Control, Placebo, Deep Anesthesia | Total |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | 63 years STANDARD_DEVIATION 10 | 65 years STANDARD_DEVIATION 11 | 64 years STANDARD_DEVIATION 11 | 64 years STANDARD_DEVIATION 11 | 65 years STANDARD_DEVIATION 13 | 64 years STANDARD_DEVIATION 11 | 63 years STANDARD_DEVIATION 12 | 65 years STANDARD_DEVIATION 12 | 64 years STANDARD_DEVIATION 11 |
| Body mass index | 28 kg/m^2 STANDARD_DEVIATION 4 | 30 kg/m^2 STANDARD_DEVIATION 6 | 28 kg/m^2 STANDARD_DEVIATION 6 | 28 kg/m^2 STANDARD_DEVIATION 8 | 28 kg/m^2 STANDARD_DEVIATION 6 | 27 kg/m^2 STANDARD_DEVIATION 5 | 27 kg/m^2 STANDARD_DEVIATION 6 | 29 kg/m^2 STANDARD_DEVIATION 6 | 28 kg/m^2 STANDARD_DEVIATION 6 |
| Race/Ethnicity, Customized African American | 2 Participants | 2 Participants | 5 Participants | 1 Participants | 2 Participants | 1 Participants | 1 Participants | 4 Participants | 18 Participants |
| Race/Ethnicity, Customized White | 49 Participants | 49 Participants | 42 Participants | 45 Participants | 44 Participants | 43 Participants | 48 Participants | 42 Participants | 362 Participants |
| Sex: Female, Male Female | 22 Participants | 14 Participants | 19 Participants | 13 Participants | 16 Participants | 13 Participants | 17 Participants | 13 Participants | 127 Participants |
| Sex: Female, Male Male | 30 Participants | 37 Participants | 28 Participants | 33 Participants | 30 Participants | 31 Participants | 32 Participants | 33 Participants | 254 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk | EG006 affected / at risk | EG007 affected / at risk |
|---|---|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 1 / 52 | 7 / 51 | 9 / 47 | 7 / 46 | 7 / 46 | 7 / 44 | 5 / 49 | 2 / 46 |
| other Total, other adverse events | 15 / 52 | 25 / 51 | 20 / 47 | 17 / 46 | 22 / 46 | 21 / 44 | 20 / 49 | 24 / 46 |
| serious Total, serious adverse events | 10 / 52 | 10 / 51 | 8 / 47 | 9 / 46 | 10 / 46 | 8 / 44 | 11 / 49 | 9 / 46 |
Outcome results
Major Perioperative Morbidity
Our primary outcome was a collapsed composite endpoint (any versus none) defined as the occurrence of at least one of sixteen major complications before hospital discharge, including sepsis, severe surgical site infection, myocardial infarction, heart failure, stroke, unstable ventricular arrhythmias, pulmonary embolism, pneumonia, respiratory failure, dialysis dependent renal failure, large pleural or peritoneal effusions, major bleeding, major wound and surgical site healing complications, vascular graft thrombosis, and 30-day mortality.
Time frame: 30 day after surgery
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Intensive Glucose Control, Dexamethasone, Light Anesthesia | Major Perioperative Morbidity | 10 Participants |
| Intensive Glucose Control, Dexamethasone, Deep Anesthesia | Major Perioperative Morbidity | 10 Participants |
| Intensive Glucose Control, Placebo, Light Anesthesia | Major Perioperative Morbidity | 8 Participants |
| Conventional Glucose Control, Dexamethasone, Light Anesthesia | Major Perioperative Morbidity | 9 Participants |
| Intensive Glucose Control, Placebo, Deep Anesthesia | Major Perioperative Morbidity | 10 Participants |
| Conventional Glucose Control, Dexamethasone, Deep Anesthesia | Major Perioperative Morbidity | 8 Participants |
| Conventional Glucose Control, Placebo, Light Anesthesia | Major Perioperative Morbidity | 11 Participants |
| Conventional Glucose Control, Placebo, Deep Anesthesia | Major Perioperative Morbidity | 9 Participants |
1 Year Mortality
All-cause mortality
Time frame: 1 year after surgery
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Intensive Glucose Control, Dexamethasone, Light Anesthesia | 1 Year Mortality | 1 Participants |
| Intensive Glucose Control, Dexamethasone, Deep Anesthesia | 1 Year Mortality | 7 Participants |
| Intensive Glucose Control, Placebo, Light Anesthesia | 1 Year Mortality | 9 Participants |
| Conventional Glucose Control, Dexamethasone, Light Anesthesia | 1 Year Mortality | 7 Participants |
| Intensive Glucose Control, Placebo, Deep Anesthesia | 1 Year Mortality | 7 Participants |
| Conventional Glucose Control, Dexamethasone, Deep Anesthesia | 1 Year Mortality | 7 Participants |
| Conventional Glucose Control, Placebo, Light Anesthesia | 1 Year Mortality | 5 Participants |
| Conventional Glucose Control, Placebo, Deep Anesthesia | 1 Year Mortality | 2 Participants |